The dose-dependent organ-specific effects of a dipeptidyl peptidase-4 inhibitor on cardiovascular complications in a model of type 2 diabetes

PLoS ONE

Volumn 11, Issue 3, 2016, Pages

  Moon, Ju Young ^a   Woo, Jong Shin ^a   Seo, Jung Woo ^a   Lee, Arah ^a   Kim, Dong Jin ^a   Kim, Yang Gyun ^a   Kim, Se Yeun ^a   Lee, Kyung Hye ^a   Lim, Sung Jig ^a   Cheng, Xian Wu ^a   Lee, Sang Ho ^a   Kim, Weon ^a  

^a Kyung Hee University Hospital   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; DIPEPTIDYL PEPTIDASE IV; DIPEPTIDYL PEPTIDASE IV INHIBITOR; GEMIGLIPTIN; HEMOGLOBIN A1C; FORKHEAD TRANSCRIPTION FACTOR; FOXO3 PROTEIN, MOUSE; GLUCAGON LIKE PEPTIDE 1; GLYCOSYLATED HEMOGLOBIN; LC15-0444; PIPERIDONE DERIVATIVE; PROTEIN KINASE B; PYRIMIDINE DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; TRANSCRIPTION FACTOR FKHRL1;

ALBUMINURIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CARDIOVASCULAR DISEASE; CELL PROTECTION; CONTROLLED STUDY; DIABETIC CARDIOMYOPATHY; DIABETIC NEPHROPATHY; DIPEPTIDYL PEPTIDASE IV BLOOD LEVEL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ENZYME ACTIVATION; ENZYME BLOOD LEVEL; ENZYME INHIBITION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEMOGLOBIN BLOOD LEVEL; IMMUNOHISTOCHEMISTRY; KIDNEY PARENCHYMA; LOW DRUG DOSE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PODOCYTE; TISSUE SPECIFICITY; TRANSTHORACIC ECHOCARDIOGRAPHY; TREATMENT DURATION; URINARY EXCRETION; ANIMAL; BLOOD; CARDIOMEGALY; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; HEART VENTRICLE FUNCTION; KIDNEY; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

ALBUMINURIA; ANIMALS; APOPTOSIS; CARDIOMEGALY; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL PEPTIDASE 4; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; DISEASE MODELS, ANIMAL; FORKHEAD BOX PROTEIN O3; FORKHEAD TRANSCRIPTION FACTORS; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; MICE; NADPH OXIDASE; PIPERIDONES; PODOCYTES; PROTO-ONCOGENE PROTEINS C-AKT; PYRIMIDINES; VENTRICULAR DYSFUNCTION;

EID: 84961226958     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0150745     Document Type: Article

References (20)

1. Holst JJ (2007) The physiology of glucagon-like peptide 1. Physiol Rev 87: 1409-1439. PMID: 17928588
2. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. (2013) Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369: 1317-1326. doi: 10.1056/NEJMoa1307684 PMID: 23992601
3. White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. (2013) Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369: 1327-1335. doi: 10.1056/NEJMoa1305889 PMID: 23992602
4. Wolf CM, Moskowitz IP, Arno S, Branco DM, Semsarian C, Bernstein SA, et al. (2005) Somatic events modify hypertrophic cardiomyopathy pathology and link hypertrophy to arrhythmia. Proc Natl Acad Sci U S A 102: 18123-18128. PMID: 16332958
5. Sauve M, Ban K, Momen MA, Zhou YQ, Henkelman RM, Husain M, et al. (2010) Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice. Diabetes 59: 1063-1073. doi: 10.2337/db09-0955 PMID: 20097729
6. Hausenloy DJ, Yellon DM (2008) GLP-1 therapy: beyond glucose control. Circ Heart Fail 1: 147-149. doi: 10.1161/CIRCHEARTFAILURE.108.810887 PMID: 19808284
7. Ha SJ, Kim W, Woo JS, Kim JB, Kim SJ, Kim WS, et al. (2012) Preventive effects of exenatide on endothelial dysfunction induced by ischemia-reperfusion injury via KATP channels. Arterioscler Thromb Vasc Biol 32: 474-480. doi: 10.1161/ATVBAHA.110.222653 PMID: 22155457
8. Woo JS, Kim W, Ha SJ, Kim JB, Kim SJ, Kim WS, et al. (2013) Cardioprotective effects of exenatide in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention: results of exenatide myocardial protection in revascularization study. Arterioscler Thromb Vasc Biol 33: 2252-2260. doi: 10.1161/ATVBAHA.113.301586 PMID: 23868944
9. Frustaci A, Kajstura J, Chimenti C, Jakoniuk I, Leri A, Maseri A, et al. (2000) Myocardial cell death in human diabetes. Circ Res 87: 1123-1132. PMID: 11110769
10. Grimm D, Jabusch HC, Kossmehl P, Huber M, Fredersdorf S, Griese DP, et al. (2002) Experimental diabetes and left ventricular hypertrophy: effects of beta-receptor blockade. Cardiovasc Pathol 11: 229-237. PMID: 12140129
11. Ohori K, Miura T, Tanno M, Miki T, Sato T, Ishikawa S, et al. (2008) Ser9 phosphorylation of mitochondrial GSK-3beta is a primary mechanism of cardiomyocyte protection by erythropoietin against oxidantinduced apoptosis. Am J Physiol Heart Circ Physiol 295: H2079-2086. doi: 10.1152/ajpheart.00092. 2008 PMID: 18805899
12. Juhaszova M, Zorov DB, Kim SH, Pepe S, Fu Q, Fishbein KW, et al. (2004) Glycogen synthase kinase-3beta mediates convergence of protection signaling to inhibit the mitochondrial permeability transition pore. J Clin Invest 113: 1535-1549. PMID: 15173880
13. Gomez L, Paillard M, Thibault H, Derumeaux G, Ovize M (2008) Inhibition of GSK3beta by postconditioning is required to prevent opening of the mitochondrial permeability transition pore during reperfusion. Circulation 117: 2761-2768. doi: 10.1161/CIRCULATIONAHA.107.755066 PMID: 18490522
14. Mega C, de Lemos ET, Vala H, Fernandes R, Oliveira J, Mascarenhas-Melo F, et al. (2011) Diabetic nephropathy amelioration by a low-dose sitagliptin in an animal model of type 2 diabetes (Zucker diabetic fatty rat). Exp Diabetes Res 2011: 162092. doi: 10.1155/2011/162092 PMID: 22203828
15. Liu WJ, Xie SH, Liu YN, Kim W, Jin HY, Park SK, et al. (2012) Dipeptidyl peptidase IV inhibitor attenuates kidney injury in streptozotocin-induced diabetic rats. J Pharmacol Exp Ther 340: 248-255. doi: 10.1124/jpet.111.186866 PMID: 22025647
16. Marques C, Mega C, Goncalves A, Rodrigues-Santos P, Teixeira-Lemos E, et al. (2014) Sitagliptin prevents inflammation and apoptotic cell death in the kidney of type 2 diabetic animals. Mediators Inflamm 2014: 538737. doi: 10.1155/2014/538737 PMID: 24817793
17. Panchapakesan U, Mather A, Pollock C (2013) Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease. Clin Sci (Lond) 124: 17-26.
18. Sharkovska Y, Reichetzeder C, Alter M, Tsuprykov O, Bachmann S, Secher T, et al. (2014) Blood pressure and glucose independent renoprotective effects of dipeptidyl peptidase-4 inhibition in a mouse model of type-2 diabetic nephropathy. J Hypertens 32: 2211-2223; discussion 2223. doi: 10.1097/ HJH.0000000000000328 PMID: 25215436
19. Kanasaki K, Shi S, Kanasaki M, He J, Nagai T, Nakamura Y, et al. (2014) Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelialto-mesenchymal transition in a therapeutic regimen. Diabetes 63: 2120-2131. doi: 10.2337/db13-1029 PMID: 24574044
20. Panchapakesan Usha, Gross Simon, Gangadharan Komala Murali, Pegg Kate, Pollock CA (2013) DPP4 Inhibition in Human Kidney Proximal Tubular Cells-Renoprotection in Diabetic Nephropathy? J Diabetes Metab S9: 1-8.